BCAB Valuation

Bioatla Inc

Add to Watchlist

Advanced Chart

0.913

+0.118(14.843%)1D

Overview
Forecast
Valuation
Earnings

BCAB Relative Valuation

BCAB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BCAB is overvalued; if below, it's undervalued.

Historical Valuation

Bioatla Inc (BCAB) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.44. The fair price of Bioatla Inc (BCAB) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：0.85

Fair

-0.77

Trailing

Forward

0.00

EV/EBITDA

Bioatla Inc. (BCAB) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -2.89. The thresholds are as follows: Strongly Undervalued below -15.02, Undervalued between -15.02 and -8.95, Fairly Valued between 3.18 and -8.95, Overvalued between 3.18 and 9.24, and Strongly Overvalued above 9.24. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-0.54

EV/EBIT

Bioatla Inc. (BCAB) has a current EV/EBIT of -0.54. The 5-year average EV/EBIT is -2.87. The thresholds are as follows: Strongly Undervalued below -15.09, Undervalued between -15.09 and -8.98, Fairly Valued between 3.24 and -8.98, Overvalued between 3.24 and 9.35, and Strongly Overvalued above 9.35. The current Forward EV/EBIT of -0.54 falls within the Historic Trend Line -Fairly Valued range.

0.00

Bioatla Inc. (BCAB) has a current PS of 0.00. The 5-year average PS is 78.87. The thresholds are as follows: Strongly Undervalued below -143.08, Undervalued between -143.08 and -32.10, Fairly Valued between 189.85 and -32.10, Overvalued between 189.85 and 300.82, and Strongly Overvalued above 300.82. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Bioatla Inc. (BCAB) has a current P/OCF of 0.00. The 5-year average P/OCF is -5.26. The thresholds are as follows: Strongly Undervalued below -22.52, Undervalued between -22.52 and -13.89, Fairly Valued between 3.37 and -13.89, Overvalued between 3.37 and 12.00, and Strongly Overvalued above 12.00. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Bioatla Inc. (BCAB) has a current P/FCF of 0.00. The 5-year average P/FCF is -5.15. The thresholds are as follows: Strongly Undervalued below -21.69, Undervalued between -21.69 and -13.42, Fairly Valued between 3.11 and -13.42, Overvalued between 3.11 and 11.38, and Strongly Overvalued above 11.38. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Bioatla Inc (BCAB) has a current Price-to-Book (P/B) ratio of -2.79. Compared to its 3-year average P/B ratio of 4.39 , the current P/B ratio is approximately -163.47% higher. Relative to its 5-year average P/B ratio of 4.34, the current P/B ratio is about -164.23% higher. Bioatla Inc (BCAB) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -134.12%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -90.94% , the current FCF yield is about -100.00% lower.

-3.20

P/B

Median3y

4.39

Median5y

4.34

-112.08

FCF Yield

Median3y

-134.12

Median5y

-90.94

Competitors Valuation Multiple

The average P/S ratio for BCAB's competitors is 0.00, providing a benchmark for relative valuation. Bioatla Inc Corp (BCAB) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Adaptimmune Therapeutics PLC

Mersana Therapeutics Inc

Senti Biosciences Inc

Sonnet Biotherapeutics Holdings Inc

Loss

35.02M

Performance Decomposition

Market capitalization of BCAB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of BCAB in the past 1 year is driven by Unknown.